Is Innate Pharma Sa Stock a good buy in 2026, according to Wall Street analysts?
The consensus among 2 Wall Street analysts covering (NASDAQ: IPHA) stock is to Strong Buy IPHA stock.
Out of 2 analysts, 1 (50%) are recommending IPHA as a Strong Buy, 1 (50%) are recommending IPHA as a Buy, 0 (0%) are recommending IPHA as a Hold, 0 (0%) are recommending IPHA as a Sell, and 0 (0%) are recommending IPHA as a Strong Sell.
According to 2 Wall Street analysts that have issued a 1 year IPHA price target, the average IPHA price target is $6.50, with the highest IPHA stock price forecast at $8.00 and the lowest IPHA stock price forecast at $5.00.
On average, Wall Street analysts predict that Innate Pharma Sa's share price could reach $6.50 by Apr 7, 2027. The average Innate Pharma Sa stock price prediction forecasts a potential upside of 354.55% from the current IPHA share price of $1.43.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.